Today: 7 February 2026
Subscribe
Browse Category

Biotech News 18 October 2025 - 28 October 2025

Alexandria Real Estate Equities (ARE) Stock Plummets to 52-Week Low After Q3 Miss – Can the Biotech REIT Rebound?

Alexandria Real Estate Equities (ARE) Stock Plummets to 52-Week Low After Q3 Miss – Can the Biotech REIT Rebound?

Stock Nosedives on Earnings News Pasadena, Calif., Oct. 28, 2025 – Alexandria Real Estate Equities (NYSE: ARE) saw its stock price collapse to a new 52-week low in Tuesday’s trading, as disappointing quarterly results and lowered guidance fueled a sharp sell-off. By mid-afternoon, shares were down roughly 16% on the day around the mid-$60sgurufocus.com, recovering slightly from an early dip to ~$65.20. The steep drop came on unusually heavy volume as investors reacted to mounting signs of trouble for the office/lab space landlord. Tuesday’s decline extends a prolonged slump for Alexandria’s stock – which has now shed about 41.9% of its
28 October 2025
·····
Co-Diagnostics (CODX) Stock Triples on Saudi JV Deal – Analysts See More Upside Ahead

Co-Diagnostics (CODX) Stock Triples on Saudi JV Deal – Analysts See More Upside Ahead

Shares Triple on Saudi JV News Co-Diagnostics stock exploded higher on Monday, triggered by an unexpected international deal. The small-cap diagnostics firm’s shares opened around $0.59 and skyrocketed, at one point up 133% by mid-morning ts2.tech. The rally accelerated throughout the day – by late morning CODX was +148% and still climbing amid wave after wave of retail buying ts2.tech. The stock ultimately closed at $1.07, up 206% in a single session ts2.tech. For context, CODX had ended the prior trading day around $0.35 and had been languishing at depressed levels after a year-long decline ts2.tech. Such a sudden threefold
28 October 2025
····
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is closing, its novel treatments may reach patients faster under Novartis’s umbrella. Investors now await the finalization of the deal (and SpinCo details), as Wall Street cheers another biotech success story in the making. 🏥💥 Sources: reuters.comreuters.combusiness-standard.combiospace.combiospace.commarketbeat.comts2.techmarketbeat.comsahmcapital.comsahmcapital.combiospace.combiospace.combusiness-standard.comreuters.combusiness-standard.comreuters.comreuters.comts2.techts2.techbiospace.combiospace.combiospace.combiospace.com
26 October 2025
···
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intradayts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had met the primary endpoints in the VIRAGE Phase 2b trial (see below). The very next trading day, Theriva disclosed a $4.0 million warrant inducement financing. Investors exercising warrants at $0.54 per share provided immediate cashts2.tech, but the announcement also trimmed the earlier stock rally – TOVX settled in the mid-$0.40 range by Oct. 16ts2.techts2.tech. In the days since, the stock has
24 October 2025
·····
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial Investing. The AFFIRM-1 trial missed both primary and secondary endpoints, and the company immediately halted its social anxiety program and launched a full strategic review Investing Globenewswire. – CEO Spyros Papapetropoulos vowed to “conserve our cash position” while exploring options to “maximize value for shareholders” Globenewswire. Neuphoria will evaluate BNC210 in PTSD (where earlier data were promising) and otherwise cut spending. – NEUP stock fell from about $15.40 on Oct 20 to roughly $5
24 October 2025
···
Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata’s stock performance this week has been nothing short of dramatic. Prior to Oct. 22, ARMP had been trading in the low-$3 range (for example, it closed around $3.41 on Oct. 16marketbeat.com). Once the late-breaking IDWeek data was announced, the shares rocketed – briefly hitting an intraday high near $16 (per some quotes) before settling at about $8.87finviz.cominvesting.com. For context, that $8.87 close is the stock’s highest level in years (FinViz shows a 52-week high of only $3.50 prior to today). By midday on Oct. 22, Investing.com already noted the stock was up ~95% on the dayinvesting.com. By market close,
22 October 2025
···
Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Stock Performance and Sector Rally Thermo Fisher’s stock price has surged in recent weeks on renewed investor optimism. After a slow start to 2025 (even a ~10% year-over-year dip early in the year), the stock turned higher in October. TS2.Tech notes the stock “rallied strongly in recent weeks – up over 11% in October after a slower start to the year” ts2.tech. On Oct. 1, Thermo Fisher jumped about +9.8% as healthcare stocks rallied following a U.S. drug-pricing deal markets.financialcontent.com. The sector’s strength continued into early October: Biogen climbed +10.9% and Thermo +9.4% on Oct. 1 ts2.tech, and TMO again
22 October 2025
····
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnightmarketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the newsgurufocus.com. The shares opened around $6–7 (up from ~$2.66 prior close) and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past yearmarketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this micro-cap biotech. Such a
21 October 2025
···
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per sharemarketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s closemarketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-datemarketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech sector ETF (XBI)
21 October 2025
···
Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

SMMT Stock’s Wild Ride in 2025 Summit Therapeutics’ share price has been on a roller-coaster ride this year. After a steady climb through late summer, SMMT spiked above $25 intraday in mid-October, then pulled back to end last week just under $21 ts2.tech. The stock fell 4.5% on Friday, Oct. 17 alone ts2.tech as traders braced for the upcoming data presentation and earnings call. Even after that dip, Summit shares remain up solidly in 2025 (low double-digit percent gains) – roughly in line with the broader biotech sector (the SPDR S&P Biotech ETF is ~+20% YTD) ts2.tech. These dramatic swings
20 October 2025
····
Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

What to Know Before Markets Open on October 20, 2025 SMMT’s Wild Stock Ride in 2025 Summit Therapeutics’ share price has experienced extreme swings this year. After a steady climb through late summer, SMMT spiked to an intraday high above $25 on Oct. 13, 2025, before pulling back to end the week just under $21stockanalysis.com. The stock fell 4.5% on Friday (Oct. 17) alonestockanalysis.com, capping a choppy few days as traders braced for the ESMO conference and earnings. Despite the recent dip, Summit’s stock is still up double-digits in 2025, roughly in line with the broader biotech sector (the SPDR
19 October 2025
····
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a week of good news: BPL-003’s FDA breakthrough, plus well-received capital raise plans. Volume on Oct. 17 was very high (tens of millions of shares), reflecting heavy trading. Over 2025 the stock has skyrocketed ~348% ts2.tech, making ATAI one of the year’s top biotech performers. Its market cap now hovers around $1.2 billion ts2.tech. Analysts have taken notice. Needham Research just initiated
18 October 2025
···
1 … 7 8 9 10 11 … 13

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop